Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $31

9/30/2026
Impact: -50
Healthcare

Goldman Sachs analyst Salveen Richter has maintained a Neutral rating on uniQure (NASDAQ: QURE) and has lowered the price target from $46 to $31. This adjustment reflects a change in the firm's outlook on the company's stock performance.

AI summary, not financial advice

Share: